Clinical Characteristics, Tumor, Node, Metastasis Status, and Mutation Rate in Domain of Epidermal Growth Factor Receptor Gene in Serbian Patients with Lung Adenocarcinoma

Zarić, Bojan; Stojšić, Vladimir; Kovačević, Tomi; Šarčev, Tatjana; Tepavac, Aleksandar; Janković, Radmila; Spasić, Jelena; Radosavljević, Davorin; Vukobradovic-Djoric, Nevena; Perin, Branislav

doi:10.1097/jto.0000000000000242

Cited by 18 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, postoperative patients with EGFR mutation show higher efficacy rates to targeted therapy and chemotherapy compared with wild-type patients [21]. Patients harboring EGFR mutation are prone to recurrence in the incision margin [22–24], and have a high metastasis rate [25]; however, they still show higher survival after recurrence [26–28]. For instance, the 5-year survival rate in patients with EGFR mutation was shown to be higher than that of cases without mutation [21], which may be related to drug sensitivity and comprehensive treatment.…”

Section: Discussionmentioning

confidence: 99%

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Nie

Gao

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

BackgroundResectable lung adenocarcinoma is dominated by peripheral distribution, and surgical resection is the main treatment protocol. However, high recurrence rate remains after surgery. Lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation has strong invasion ability, but the effects of this mutation on local invasion in early lung adenocarcinoma have been rarely studied. This study aimed to assess the effects of EGFR mutation on local invasion in resectable lung adenocarcinoma.MethodsA retrospective analysis of 103 patients clinically diagnosed with peripheral lung adenocarcinoma was included. They underwent preoperative bronchoscopy, which indicated grades 2 or 3 bronchial involvement (lumen of the lobe or segment). The associations of EGFR mutation with pleural invasion, endobronchial metastasis, and lymph node metastasis were analyzed according to pathologies of pleural invasion and lymph node metastasis, as well as EGFR gene mutation detected by postoperative pathological specimens. Statistical analyses were performed by unpaired Chi-square test using the SPSS16.0 software.ResultsIn patients with EGFR mutation, pleural invasion, endobronchial metastasis, and lymph node metastasis rates were 62.5, 39.1, and 34.4%, respectively, indicating statistically significant differences (p = 0.003). Meanwhile, the pleural invasion rate in patients with wild-type EGFR was 43.6%, significantly reduced compared with patients with mutated EGFR (62.5%; p = 0.018). In addition, the endobronchial metastasis rate in patients with wild-type EGFR was 17.9%, significantly lower than in patients with EGFR mutation (39.1%; p = 0.005). However, lymph node metastasis rates were similar between EGFR mutated and wild-type patients (34.4 vs 25.6%, respectively, p > 0.05).ConclusionsEarly resectable lung adenocarcinoma patients with EGFR mutation showed a higher rate of local invasion compared with those harboring wild-type EGFR. This finding provides a basis for improved therapy.Trial registrationThis study was supported by Project of Medical and Health Science Technology in Shandong Province (2015WS0376)

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Nie

Gao

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…In the first major study on EGFR mutation status of patients from Serbia, EGFR mutations were detected in 42/360 (11.7%) patients with lung ADC 37 . Contrary to these results, we detected EGFR mutations in a significantly smaller percentage (2/60; 3.3%).…”

Section: Discussionmentioning

confidence: 99%

“…Contrary to these results, we detected EGFR mutations in a significantly smaller percentage (2/60; 3.3%). Deletions in exon 19 are most often detected by applying the Cobas® EGFR Mutation Test 35,37 . We did not detect this type of mutation, and the results of our research are most likely the consequence of a smaller number of patients involved in the research, as well as a smaller percentage of EGFR mutated lung ADC.…”

Section: Discussionmentioning

confidence: 99%

Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Background/Aim. Adenocarcinoma of the lung is the most common histological type of lung cancer. The most reliable method in detecting EGFR mutations is real-time PCR. It is recommended to sample three to five biopsy samples with a minimum of 200-400 preserved tumor cells. We analyzed the suitability of biopsy samples for EGFR molecular testing in lung adenocarcinoma.Methods. This retrospective analysis included 60 patients diagnosed with lung adenocarcinoma in the Institute for Pulmonary Diseases in Sremska Kamenica, during the period 2010-2015. Biopsy samples were obtained using transbronchial, bronchoscopic or catheter biopsy procedure. All cases included the identification of morphometric parameters, concentration of isolated DNA and EGFR mutations. The proportion of tumor in biopsy samples was assessed in histological sections using computer-aided morphometry. Results. Biopsy samples were most commonly obtained by transbronchial biopsy (63%). In 35% of cases there were one and two biopsy samples. More than 10% of tumor cells were found in 68% of cases, while the majority of cases (33%) had between 200 and 500 of tumor cells and only 8% of cases had between 20 and 50 tumor cells. The average concentration of DNA in all analyzed samples was 5.81 ng/µl and was significantly lower in samples provided by catheter biopsy. Only two cases with mutations were detected, and there was no statistically significant difference between the concentrations of isolated DNA in wilde type and mutated EGFR adenocarcinoma. Invalid results were found in 10% of cases. Conclusion. Biopsy samples are suitable for EGFR molecular testing in lung adenocarcinoma.

show abstract

“…5 A few retrospective studies with low numbers of patients reported controversial results in African American patients, with mutation rates ranging from 5% to 19% and a significant association with smoking status or sex. [6][7][8][9] With a 36% mutation rate, the results found in our population are much higher than expected in African American populations or white populations of mainland France.…”

Section: Egfr Mutation Ratementioning

confidence: 98%

Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population

Leduc

Ahomadegbé

Agossou

et al. 2016

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Clinical Characteristics, Tumor, Node, Metastasis Status, and Mutation Rate in Domain of Epidermal Growth Factor Receptor Gene in Serbian Patients with Lung Adenocarcinoma

Abstract: Mutation rate in domain of EGFR gene in investigated lung cancer population is in range with reported data in Caucasian race. Smoking, T descriptor and gender were found to be related to the EGFR status.

Cited by 18 publications

References 15 publications

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma

Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population

Contact Info

Product

Resources

About